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Hemodialysis with cellulosic membrane is not associated with net
generation of free J.32 microglobulin (fi2m). J. Chanard, 0. Toupance, P.
Gillery, A. Wynckel, P. Bindi, S. Lavaud, Centre Hospitalier Univer-
sitaire, Reims, France. Serum f32m concentration decreases during
hemodialysis performed with highly permeable membranes. Conflicting
results have been observed during duprophane dialysis which is not
permeable for this protein. We have investigated the hypothesis that the
apparent increase of free 132m level could result from extracellular fluid
volume (EVC) contraction. Using inulin, ECV was measured before
and two hours after a dialysis session with a sodium dialysate concen-
tration of 145 mmol/liter in 15 patients. Transcellular water shift and
changes in /32m concentration were calculated from total body water
changes (ultrafiltration) and ECV. ECV decreased from a predialysis
value of 16.4 3.5 liter (mean SD; 24.9% body wt). Ultrafiltration was
only 2.9 0.9 liter, indicating concomitant water shift from ECV to
intracellular fluid space. The ECV contraction was about 150% of the
fluid removed by ultrafiltration. A significant decrease in corrected /32m
concentration was found for high flux membranes. However, postdial-
ysis 32m levels did not change significantly after dialysis with cellulosic
membranes. With cuprophane the predialysis level was 53.9 13.1 and
the postdialysis level 43.2 8.7 mg per liter of extracellular water (NS).
In 5 patients sham dialysis was performed for 2 hr before a regular
session. Serum f32m levels did not increase with cuprophane, and
decreased significantly by adsorption onto synthetic membranes (poly-
acrylonitrile, polysulfone, polymethylmethacrylate). In conclusion, the
apparent increase of serum /32m concentration measured during hemo-
dialysis with cellulosic membrane results from ECV contraction. There
is no appreciable net release of /32m. These results have to be taken into
account for any pathogenic mechanism of the f32m-derived amyloidosis
occurring in long-term hemodialyzed patients.
Immunopathological consequences of active immunization against mu-
rifle renin in spontaneously hypertensive and normotensive rats. C.
Guettier, N. Hinglais, R. Reade, S. Sayah, D. Gentric, J. P. Camilleri,
P. Corvol, J.B. Michel, Inserm U36-17, rue du Fer-â-Moulin and Hop
Broussais, Anatomopathologie, Paris, France. Spontaneously hyper-
tensive (SHR) and normotensive (WKY) rats were actively immunized
with mouse renin. Control SHR and WKY were immunized with bovine
serum albumin. Immunized animals had high titers of renin antibodies
with a significant drop in blood pressure in SHR. In SHR controls,
histological study showed rare and mild concentric hyperplasia of
arterioles and interlobular arteries. Immunostaining of renin was poorly
positive in the juxtaglomerular apparatus (JGA) in about 10% of
glomerular sections. Antifibrinogen and anti-IgG staining produced few
positive responses in the JGA. In SHR immunized animals, the surface
of each kidney appeared granular. A perivascular mononuclear cell
infiltration surrounded the JGA, with strips of fibrosis along the
interlobular arteries. Tubules were atrophic. No vascular necrosis was
observed. Hyperplasia of renin positive cells of about 25% of glomer-
ular sections was observed; this hyperplasia correlated roughly with the
extension of perivascular deposits and fibrosis. Immunofluorescence
revealed large irregular deposits of IgG in the JGA and arteriolar wall of
preglomerular arteries. Leucocyte phenotyping with monoclonal anti-
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bodies essentially showed T lymphocytes of helper phenotype and
many Ia positive cells. Few macrophages were stained, and no B
lymphocytes were revealed by anti-kappa light-chain antibody. This
suggests that most of the Ia positive 0X6 cells were T lymphocytes of
helper/inducer phenotype (W3/25). Electron microscopy showed elec-
tron dense deposits in the wall of preglomerular arterioles, situated
between myoepithelial cells which were intact. Mononuclear cell infil-
tration of lymphocytes and monocytes was localized around the exter-
nal side of the arteriole. Some tubules which were in contact appeared
atrophic with deposits in their basement membrane. Glomeruli were
usually normal. Active murine renin immunization provokes renal
antoimmune disease in the rat, which is specifically localized to afferent
arterioles and interlobular arteries, where the antigen is synthesized.
This represents an original model of renal autoimmune angeitis.
Influence of cyclosporine (CsA) on adriamycin (A) induced nephrotic
syndrome (NS) in the rat. J.C. Aldigier, A. Out,frakh, J. Moreau, M.
Rigaud, C. Leroux-Robert, Service de Nephrologie, Service de Bio-
chimie, CHU Dupuytren, Limoges 87000, France. We have investi-
gated the influence of CsA on proteinuria (P), urinary excretion (U) and
glomerular synthesis of cyclooxygenase metabolites (TXA2, PGE2, and
6-keto-PGF1) and lipoxygenase (11, 12 and 15-HETEs) metabolites
during A induced NS in the rat. Four groups of 5 Sprague-Dawley rats
were used: I (A: 5 mg/kg iv. at D0), II (solvent at D0); III (CsA: 14
mg/kg/day during 50 days) and IV (A + C5A). CsA had no effect on the
evolution of A induced NS: D50 P (mg/24 hr; mean SD), I = 840
60*, II: 10 3; III: 12 5.5; IV: 2, 450 80* (*P < 0.01 vs. II). U of
TXB2 increased (ng/24 hr, mean SD); at D50 I = 42 8*; II: 13.2
2; III: 36.7 10*; IV: 107 18** (*P < 0.05, **p < 0.01 vs. H).
Glomerular synthesis of cyclooxygenase and lipoxygenase derivatives
by isolated glomeruli was unaltered at D50 for all 4 groups. We conclude
that CsA does not influence the progression of A induced NS in the rat,
which suggests that CsA has no influence on A induced anomalies
resulting in proteinuria.
Late recovery of renal function in malignant hypertension with renal
failure. F. Haddoum, P. Dosquet, Ph. Sporer, B. Viron, F. Mignon,
Department of Nephrology, HOpital Tenon, Paris, France. We report 7
cases of malignant hypertension with renal failure (RF) requiring
hemodialysis (HD) for a period time exceeding 8 weeks. In 4 cases
(group I) late recovery of renal function (LRRF) was observed then HD
was discontinued after 16, 28, 33, and 42 weeks of treatment, and they
are still HD-free after respectively 5, 11, 6 and 71 months follow-up
(creatinine clearance, between 15 and 40 mI/mm). Three other cases
(group II) still require HD after 45, 53 and 79 weeks of treatment. At
presentation all patients (4 blacks, 3 whites) mean age 32 years had
distolic pressure  130 mm Hg, grade III or IV at fundoscopy, diuresis
 1 1/24 hr, proteinuna range 0.5 to 2 g/24 hr. Renal arteriography
performed in 6 cases (4 of gr I, 2 of gr II) demonstrated typical lesions
of malignant nephrosclerosis. Microangiopathic hemolytic anemia was
present in 3 cases (2 of gr I, 1 of gr II). The 4 patients who recovered are
characterized by: 1) A histologic pattern with malignant nephrosclerosis
lesions affecting predominantly arteries with preserved, only ischemic,
glomeruli. 2) Normal kidney size. 3) Sudden crises of hypertension and
rapid progression of RF. 4) Short delay for initiating HD with ultrafil-
tration (mean: 13 days) contributing to easy control of hypertension, in
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contrast with group II where this interval is longer (mean: 53 days) and
control of hypertension more difficult and delayed. The long period
necessary for resolution of vascular lesions under hypotensive therapy
may explain the LRRF in malignant hypertension. The LRRF in our
young patients of group I suggest beginning HD early and hypotensive
therapy in malignant hypertension. Renal transplantation must be
proposed only after a long period of dialysis.
Evolution of systemic lupus erythematosus (SLE) in 32 chronic hemo-
dialyzed patients: A retrospective study in Paris and its region. P.
Dosquet, F. Mignon, Department of Nephrology A, Hôpital TENON,
Paris, France. We retrospectively studied 32 patients treated for
end-stage SLE nephritis by hemodialysis (HD) during at least 6 months
since 1980, in 16 HD centers in Paris and its region. The patients (29
women, 3 men) were 23.2 7.8 years old at the beginning of SLE. HD
began 5.9 4.4years after the onset of SLE. The follow-up in HD was
from 6 months to 8 years (4.1 2.5 years). No patient died during HD
follow-up. Seven patients (22%) presented SLE evolution at the onset
of HD. Twenty-two patients (69%) presented no flare up during the
follow-up. Eight patients (25%) presented only one flare up, occurring
between 2 months and 4 years after the onset of HD treatment (mean 2
years). The clinical symptoms consisted of arthralgias and fever (5
cases), pericarditis (2 cases), SLE rash (2 cases) and/Coombs positive
anemia (1 case). All the signs disappeared quickly with steroid therapy
alone. Only 2 patients (6%) presented severe and recurrent flare ups, 1
month to 4 years after the onset of HD: cutaneous vasculitis (3 times)
and pericarditis (twice). These flare ups were also easily controlled by
steroid therapy alone. Flare ups were observed more frequently when
SLE was still active at the onset of HD. Clinical and serological flare
ups are not rare in patients treated by HD for SLE nephritis. However,
severe or recurrent flare ups are rare in our experience. No patient died
of an SLE flare up. Clinical and serological data must be regularly
checked in SLE patients treated by HD, especially if SLE was still
active at the onset of HD.
Familial infantile nephrotic syndrome with ocular anomalies. G. Glas-
tre, P. Cochat, S. Colon, R. Bouvier, X. Cottin, D. Giffon, C. Wright,
F. DUoud, L. David, Pediatric Nephrology Unit, F. Herriot Hospital,
Lyon, France. Two Portugese children (I male, I female) born from
consangineous parents experienced early infantile nephrotic syndrome,
eye changes (nystagmus + bilateral myosis + cataracts), axial hypoto-
nia and micropenis in the male. Three observations in the literature
have reported comparable data (YA Barakat, mt J Pediatr Nephrol 3:
33, 1982, YE Martul, Clin Nephrol 28:161, 1987). The course was
quickly unfavorable (untractable nephrotic syndrome, renal failure,
metabolic disorders, sepsis) and both patients died at 8 months of age.
The pathologic study showed identical lesions in both children. His-
tologic follow-up was made in one: 1) renal biopsy (age 2 mos.) 2) left
nephrectomy (age 3 mos.) and 3) right nephrectomy (age 4 mos.).
Glomerular involvement was predominant from the onset; it consisted
initially in endocapillary proliferation of focal segmental fibrosis and
mesangial thickening. Subsequently, epithelial crescents (50% of gb-
meruli) and extensive mesangial sclerosis occurred. Unusual tubular
lesions (especially intensive mitotic activity and anisocaryosis) ap-
peared on the late nephrectomy fragment, associated with dilatations
and epithelial differentiation. The immunofluorescence study showed
diffuse peripheral submembranous 1gM deposits mainly in the mesan-
gium. The electron microscopy examination showed major changes in
the glomerular basement membrane with alternating of thick and thin
zones; the lamina densa was very slight and split, with irregular
expansions, most of them on the external side. The association of such
renal lesions, different from the previously described diffuse mesangial
sclerosis with specific eye changes, suggests a new form of familial
infantile nephrotic syndrome, probably supported by autosomal reces-
sive inheritance.
Detection of lead intoxication in chronic renal failure patients. Impor-
tance of determination of delta amino levulinic dehydrase acid (ALA-D).
M. Kessler, P. Y. Durand, T. Cao Huu, J. Chanliau, M. Duc, Service de
Néphrologie, Service de Médecine J, CHRU de Nancy-Brabois, F
54511 Vandoeuvre Les Nancy Cedex, France. Determination of ALA-D
is at present considered as the most sensitive test for detecting chronic
lead intoxication in individuals with normal renal function (NRF;
normal > 0.40 micromoles of porphobilinogen formed per milliliter of
RBC per hour). The level of ALA-D was analyzed in 199 chronic renal
failure patients, dialyzed and nondialyzed, some of whom were living in
an area with endemic high water lead content. These levels were
compared with those of a control population with normal renal function
and also with those of renal transplant patients who were exposed to the
same risk. In the absence of lead intoxication the level of ALA-D is
significantly lower in chronic renal failure patients, dialyzed and non-
dialyzed than in both normal renal function patients and renal transplant
patients. For an ALA-D level <0.40 the incidence of lead intoxication
in chronic renal failure patients is lower thant in those with normal renal
function. However, in chronic renal failure patients there is a strong
inverse relationship between ALA-D and the lead extracted by chela-
tion (EDTA Ca). We can therefore state that in both chronic renal
failure patients and those with normal renal function, the determination
of ALA-D is equally important and significant under the condition that
we establish a new normal value at 0.15.
Treatment of severe arterial hypertension in dialysis and renal trans.
plant patients by means of arterial alcoholization of native kidneys. M.
d'Espine, P.A. Schneider, M. Val/otton, M. Leski, Departments of
Medicine and Radiology, Hopital Cantonal Universitaire, 1211
Geneva, Switzerland. We have attempted to abolish renin secretion
from the native kidneys of 4 renal transplant patients and 1 hemodial-
ysis patient. Renin concentration obtained by selective renal vein
sampling showed in all cases a ratio of renin concentration in renal
vein/vena cava greater than 2. Ablation was achieved with 96% ethanol
injected by means of occlusive catheterization of the renal artery. We
used one to three injections averaging 6 mIs of alcohol per kidney. Two
kidneys also received particulate embolization. Previous treatment of
hypertension required an average of 2.6 drugs per patient. After a
median period of 2 months, 2 patients are without treatment and 3 take
only one drug. Side effects, lasting less than 48 hours, consisted of fever
and loin pain. In conclusion, we have treated with success, 5 cases
selected on the basis of differential renin levels, avoiding surgical
nephrectomy and requiring only 3 days of hospitalization.
Comparison of two hemodialysis membranes, polyacrilonitrile (AN96)
and cellulose acetate (CA) on complement and coagulation activation. S.
Moll, J. Schjfferli, P. de Moerloose, M. Levy, M. Leski, Département
de Médecine, Hopital Cantonal Universitaire de Genéve, Switzerland.
Two hemodialysis membranes, polyacrilonitrile (AN69) and cellulose
acetate (CA), were compared for their effects on the coagulation
system. Two groups of 5 patients, in dialysis for more than 5 years,
were successively dialyzed for 4-week periods with each type of
membrane. We measured C3a (complement activation), platelets and
beta-thromboglobulin (BTG) (platelet activation), activated partial
thromboplastin time (aPTT), thrombin-antithrombin complex (TAT)
and fibrinopeptide A (FPA) (coagulation), and D-Dimer (DDI) (fibrino-
lysis), using C-reactive-protein (CRP) as a control for dilutional effects.
As already known, CA activated complement (P < 0.01) whereas AN69
did not. By contrast AN69 activated coagulation (increase in TAT and
FPA P < 0.05) which was not modified by CA. Platelets, BTG and DDI
were not modified significantly by either membrane. It is remarkable
that bioincompatibility may be totally dissociated for two different
biological systems (complement and coagulation); further experiments
of bio-incompatibility should include measurements of these two sys-
tems.
Endogenous digitalis-like substance (EDLS) and hypertension in hemo-
dialysis patients (HD) versus CAPD patients. R. Donath, L. de Clerck,
H. Favre, Division of Nephrology, Hôpital Cantonal Universitaire,
1211 Geneva, Switzerland. Elevation of the blood levels of EDLS has
been reported in several situations of hypertension. One of the accepted
advantages of CAPD versus HD is a better control of blood pressure in
end-stage renal disease patients despite the fact that renin and aldoste-
rone increase on treatment. Therefore blood levels of EDLS have been
compared in 10 patients treated by HD versus 10 patients treated by
CAPD. EDLS was measured by a receptor assay in the blood of HD
patients before and after dialysis and in the blood and dialysate fluid of
CAPD patients. Results: systolic blood pressure averaged 149 6 mm
Hg in HD patients versus 132 1.8 mm Hg in CAPD (P < 0.007). Ten
percent of HD patients versus 30% of CAPD patients did not receive
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hypotensive treatment. Plasma levels of EDLS (mean SD) were 114
28.6 nmol/liter in I-ID patients versus 87.6 21.9 in CAPD patients (P
< 0.03). EDLS concentrations in the blood were identical before and
after dialysis in hemodialysis patients (P = 0.2). EDLS removed in the
dialysate fluid of CAPD patients averaged 161 nmol/24 hr which
corresponds to the physiological amount of EDLS eliminated in the
urine of normal subjects on the same salt intake. Conclusion: CAPD
removed physiological amounts of EDLS while HD did not. Therefore
the normalization of the metabolism of EDLS by CAPD may explain
the better control of blood pressure by this method as compared to
hemodialysis.
Prognosis on dialysis of 31 patients after bilateral nephrectomy for
bilateral renal cancer. A. Gre/laud, M. Calamai, J.P. Charmes, M.
Benzakour, G. Albouze, C. Leroux-Robert, Centre d'Hemodialyse,
36000 Chateauroux, Service de Nephrologie, Hópital Universitaire
Dupuytren 87042 Limoges, France. The prognosis of patients on
dialysis after bilateral nephrectomy for bilateral renal cell carcinoma is
rarely reported in the literature. A simple questionnaire was sent to 204
dialysis centers to determine these patients' survival. Responses were
obtained from 103 dialysis centers allowing us to review 31 cases of
bilateral nephrectomy for renal carcinoma - 9 synchronous and 22
asynchronous bilateral renal cell carcinoma (with a mean interval of 68
months between the two tumors). Twenty-one males and 10 females
(average age 53 years) were studied. All had bilateral nephrectomy and
required dialysis (hemodialysis or CAPD). In three cases metastases
were detected before binephrectomy. Metastases appeared 11 .5 months
after binephrectomy in 21 patients. Two patients were transplanted
after 15 and 16 months on dialysis; they died 11 months later. Survival
was longer in patients with synchronous as compared to asynchronous
bilateral renal carcinoma. Thirteen patients died from cancer progres-
sion and 7 from other causes. The overall postbinephrectomy actuarial
survival shows survival rates of 70% for 1 year, 48.5% for 2 years and
23% for 3 years. These results need to be compared with those of
nonsurgically treated patients with bilateral renal cell cancer.
Influence of dialysis membranes on plasma catecholamines in hemodi-
alysis patients. F. Cogny Van Weydevelt, J.P. Charmes, G. Lachatre,
G. Nicot, P. Peyronnet, C. Leroux-Robert, Service de Nephrologie,
Service de Pharmacologie Clinique, Hôpital Universitaire Dupuytren,
87042 Limoges, France. Free and total plasma catecholamines are
increased in hemodialysis patients. After dialysis we observed a de-
crease in total catecholamines which nevertheless remain higher than
normal levels and a significant increase in free (active) epinephrine (E)
and norepinephrine (NE). Before and after hemodialysis we measured
free and total E and NE and total dopamine (DA) using HPLC in 8
patients (average age 58.3 years) successively dialyzed with a cu-
prophan membrane, then with a polyacrylonitrile membrane (PAN),
and in 10 patients (average age 58.8 years) successively dialyzed with a
cuprophan membrane then with a cellulose acetate membrane. In the
two groups dialysis parameters were the same in terms of time, duration
of treatment, composition of dialysis fluids and ultrafiltration. Catechol-
amines always moved in the way we expected. But after dialysis with
PAN and cellulose acetate membranes we observed lower levels of
plasma catecholamines. With the PAN membrane especially, the de-
crease in total NE after dialysis was more significant (P < 0.01) and the
increase in free NE less significant (P < 0.05) as compared to the
cuprophan membrane. These results could be linked to a possible
decrease in vascular complications with dialysis membranes which are
least bio-incompatible.
Use of calcium citrate as unique phosphate binding agent for hemodi-
alyzed patients. V. Joyeux, P. Ic Pogamp, C. Charasse, D. Chevet,
Nephrology, Hemodialysis Unit-C.H. U. Rennes, France. The aim of
this study was to verify the efficacy and the good tolerance of calcium
citrate as a unique phosphate binding agent in hemodialyzed patients(HD) as proposed by Cushner et al. We have selected 26 HD patients
often aluminum overloaded with difficult control of blood phosphate
level by calcium carbonate alone (4 pts) and/or aluminum compounds
(21 pts). Mean age was 59 8 years, with a dialysis treatment of 42.5
40 months. Composition of dialysate was calcium: 3 or 3.5 mEq/liter,
acetate: 35 mEq/liter (4 pts) or bicarbonate: 34 mEq/liter (22 pts).
Calcium citrate administration was started at 5 g/day (1.05 g/day of
calcium element) and afterwards adjusted to a maximal dose of 15g/day.
All aluminum compounds and other calcium supplements were discon-
tinued. Mean length of calcium citrate treatment is 10.6 3.1 months
(286 patient months). The efficacy was ascertained monthly on midweek
blood levels of calcium, phosphate and total C02, compared with the
same parameter during the baseline 6 previous months (two-tailed
Student t-test). Results are summarized in the following table.
Baseline 1 month 3 months
Calcium mmol/liter 2.3 2.36 2.38a
Phosphate mmol/liter 1.9 1.92 1.76
CO2T mEq/liter 20 22 2l.9a
Aluminium sg/liter 48 — 27
Ca.citrate g/day 0 6.7 7.1
Al(OH)3 glday 1.5 0 0
CaCO3 g/day 3.2 0 0
Nb pts 26 26 26
6 months 9 months 12 months
Calcium mmol/liter 248b 2.43a 2.45a
Phosphate mmol/liter 1.89 1.86 1.71
CO2 T mEq/liter 251b 22.8a 23
Aluminium sg/liter 22 — —
Ca.citrate g/day 8.1 9.3 9
Al(OH)3 g/day 0 0 0
CaCO3 g/day 0 0 0
Nbpts 21 18 13
a p < 0.05; b p < 0.001
Without significant modification of vitamin D treatment, serum calcium
phosphate levels were as well controlled by calcium citrate alone as by
calcium carbonate mostly associated with aluminum compounds. A
significant rise of serum total CO2 and calcium levels was observed.
Only 8 transient asymptomatic hypercalcemias (2.7% patient month
rate) occurred. Clinical tolerance was excellent with a better compli-
ance than with previous agents. We conclude that calcium citrate is an
effective, well-tolerated non aluminum-containing phosphate binding
agent for hemodialyzed patients. However, more long-term efficacy has
to be proved.
Cholesterol atheroembolic renal disease: A report of 13 cases. D.
Fleury, Ph. Vanhille, B. Mougenot, V. Lemaltre, P. Gobert, Depart-
ment of Nephrology Valenciennes, Hôpital Tenon, Paris, France.
Cholesterol atheroembolic renal disease (CARD) is the most usual
manifestation of atheroembolic disease. From 1981 to 1988, 13 patients
(pts) with CARD were studied: 6 pts with acute renal failure (ARF,
group 1), 6 pts with chronic renal failure (CRF, group 2). In the last pt,
microhematuria and mild HTA were the only abnormalities. In all pts
CARD was established by renal biopsy (12 percutaneous, 1 open
biopsies). Common findings in the two groups were: 1) males over 60
years old with history of atheromatous disease, 12 of 12; 2) urinary
signs: proteinuria (0.5 to 4.8 glday) 11 of 12 and microhematuria, 6 of 12;
3) HTA (diastolic blood pressure  100 mm Hg) 12 of 12; 4) increased
erythrocyte sedimentation rate (ESR) 60 mm, 12 of 12; and few
immunological abnormalities: low titer of ANA 6 of 12, low C3 1 of 12,
high C3d 3 of 6, absence of antineutrophil cytoplasm antibodies 7 of 7.
Particular findings in group 1 (ARF) were: I) known CRF (creatinine 2.5
mgldl); 2) inciting fractors 3 of 6: angiography 2 of 6, anticoagulant 1 of
6; 3) constant eosinophilia 6 of 6, >1000/mm3 3 of 6; 4) extrarenal
symptoms 4 of 6: purple toes with cholesterol clefts in the dermal
vasculature 3 of 6, livedo 1 of 6; 5) 3 deaths among the 4 of 6
hemodialyzed pts, 1, 2 and 7 months after diagnosis. Group 2 (CRF)
was characterized by: 1) mean serum creatinine level of 2.5 mg/dl; 2)
unusual inciting factors 1 of 6 and cutaneous symptoms 1 of 6; 3)
eosinophilia 3 of 6; 4) 3 deaths, 1, 2-1/2 and 10 months after diagnosis.
In our unit, CARD was diagnosed in 4.2% kidney biopsies performed on
pts over 60 years old with renal failure. The diagnosis should be
considered in male older pts with renal failure, hypertension, increased
ESR and atheromatous disease. ARF with inciting factors and cutane-
316 Abstracts
ous lesions allowing noninvasive skin biopsy precludes renal biopsy.
However, without these factors, percutaneous renal biopsy is an
adequate procedure to make the definitive diagnosis of CARD.
Long-term hemodialysis with An 69 membrane is associated with low
prevalence of carpal tunnel syndrome. J. Chanard, P. Bindi, H. Maheut,
J-J. Dion, S. Lavaud, F. Lacour, 0. Toupance, Centre Hospitalier et
Universitaire, et Clinique Mutualiste, Reims, France. Carpal tunnel
syndrome (CTS) and osteoarthropathy related to p2 microglobulin-
derived amyloidosis are frequently encountered in long-terni dialysis
patients. Different authors have suggested that the dialytic strategy and
particularly the use of biocompatible high-flux hemodialysers may
prevent or postpone symptomatic amyloidosis. Eighty-six patients from
two Centers in the same city, treated similarly for more than 7 years
with plate high-flux dialyzers equipped with the AN 69 membrane,
entered the study. Thirty-two patients were treated exclusively with
AN 69 since the beginning of dialysis (group I) and 54 were first treated
with cuprophane membrane (CP) and then with AN 69 (group II). CTS
required surgery in 16 group II patients and only in one group I patient
(P <0.001). Prevalence of CTS did not differ between the two Centers.
The average time exposure to artificial membrane was 5299 hr on AN 69
in group I versus 2969 hr on CP and 3854 hr on AN 69 in group II. In
group II, exposure to CP was significantly longer (P < 0.001) in patients
with CTS than in patients without the syndrome (5304 vs. 1980 hr). We
conclude that dialysis with high-flux biocompatible polyacrylonitrile
AN 69 membrane is definitely associated with a very low incidence of
CTS when compared with CP membrane.
Early destructive spondylarthropathy in hemodialysis patients. P.
Bindi, J-J. Dion, S. Lavaud, J. Gougeon, 0. Toupance, J. Chanard,
Centre Hospitalier et Universitaire, Reims, France. Destructive
spondylarthropathy (DSA) is one of the most spectacular osteoarticular
manifestations of chronic uremia in long-term dialysis patients. Micro-
crystalline deposits and amyloidosis may be relevant pathogenic mech-
anisms. In a series of 100 patients dialyzed for 3 months to 17 years,
DSA was diagnosed in 11 patients. Lower cervical spine was involved
in 10 cases and dorsal spine in one case. Two groups of patients were
selected: in 4, DSA was found within the first 41 months of dialysis
(group!) and in 7, after 106 months of dialysis (group II). Group I was
associated with older age, chondrocalcinosis (2 of 4), absence of overt
osteoarticular bone defects and carpal tunnel syndrome (CTS). Group
II was associated with absence of radiological chondrocalcinosis,
presence of shoulder pain (6 of 7), juxtaarticular bone cysts (7 of 7) and
CTS (6 of 7). Parathyroidectomy was performed in 5 of 7 patients.
Amyloidosis was found in 2 patients who required surgery. In conclu-
sion, DSA may be seen early in the course of dialysis, without general
amyloid involvement. A particular finding of this study is the discovery
of radiological chondrocalcinosis in half of these patients, which is a
well recognized factor of DSA in nonuremic subjects.
Localization of the human decay accelerating factor (DAF) in normal
kidney and in 36 cases of renal diseases. L.H. Noel, F. Porteu, R.C.
Monteiro, L. Halbwachs-Mecarelli, M.K. Pangburn, and P. Lesavre.
INSERM U25 and Department of Nephrology, Hopital Necker, Paris,
France, and Department of Biochemistry, University of Texas Health
Sciences Center, Tyler, Texas 75710, USA. The decay accelerating
factor (DAF) is a membrane glycoprotein which controls the comple-
ment activation by dissociating the classical and alternative C3 conver-
tases. DAF is widely distributed on endothelial cells, peripheral blood
leukocytes, platelets and erythrocytes. Trace amounts of DAF are
present in plasma, tears and urine. Polyclonal anti-DAF antibodies have
been obtained in rabbit and used by indirect immunofluorescence on
kidney sections; normal kidneys (N = 5), IgA nephropathy (N = 1);
dense deposits diseases (N = I); minimal change nephropathy (N = 2);
cryoglobulinemia (N = I); rapidly progessive GN (N =2); tubulointer-
stitial nephritis (N = 5); SLE nephritis (N = 3); diabetic nephropathy(N = 3); myeloma (N 2); transplanted kidneys (N = 16). DAF was
present in the basement membrane of distal tubular cells and in the
cytoplasm of the lacis cells from the juxtaglomerular apparatus (JGA) in
2 of the 5 normal kidneys and in 16 of the 36 diseased or transplanted
kidneys. DAF was seldom present on vascular endothelial cells. Thus
the DAF distribution was almost identical in normal and diseased
kidneys. Interestingly enough the DAF expression was increased in
SLE nephritis where DAF was found in the mesangium (in 2 of the 3
cases of the the lupus proliferative nephritis studied). The presence of
DAF in pathologic kidney specimens was not correlated with comple-
ment activation. Indeed no relationship between DAF and Clq, C4 or
C3 deposits has been observed. Conclusions: DAF is present in the
cytoplasm of the lacis cells from the JGA where its role remains to be
determined, The localization of DAF was almost identical in normal and
diseased kidney. The only exception was proliferative lupus nephritis
where DAF was expressed in the mesangium.
